BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pimpin L, Cortez-Pinto H, Negro F, Corbould E, Lazarus JV, Webber L, Sheron N; EASL HEPAHEALTH Steering Committee. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018;69:718-735. [PMID: 29777749 DOI: 10.1016/j.jhep.2018.05.011] [Cited by in Crossref: 211] [Cited by in F6Publishing: 190] [Article Influence: 52.8] [Reference Citation Analysis]
Number Citing Articles
1 Costentin CE, Sogni P, Falissard B, Barbare JC, Bendersky N, Farges O, Goutte N. Geographical Disparities of Outcomes of Hepatocellular Carcinoma in France: The Heavier Burden of Alcohol Compared to Hepatitis C. Dig Dis Sci 2020;65:301-11. [PMID: 31346950 DOI: 10.1007/s10620-019-05724-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Roerecke M, Vafaei A, Hasan OSM, Chrystoja BR, Cruz M, Lee R, Neuman MG, Rehm J. Alcohol Consumption and Risk of Liver Cirrhosis: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2019;114:1574-86. [PMID: 31464740 DOI: 10.14309/ajg.0000000000000340] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 18.0] [Reference Citation Analysis]
3 Trieb M, Rainer F, Stadlbauer V, Douschan P, Horvath A, Binder L, Trakaki A, Knuplez E, Scharnagl H, Stojakovic T, Heinemann Á, Mandorfer M, Paternostro R, Reiberger T, Pitarch C, Amorós A, Gerbes A, Caraceni P, Alessandria C, Moreau R, Clària J, Marsche G, Stauber RE. HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure. J Hepatol 2020;73:113-20. [PMID: 32061870 DOI: 10.1016/j.jhep.2020.01.026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
4 Cheng Q, Ding H, Fang J, Fang X, Liu H, Wang J, Chen C, Zhang W. Aquaporin 9 Represents a Novel Target of Chronic Liver Injury That May Antagonize Its Progression by Reducing Lipotoxicity. Oxid Med Cell Longev 2021;2021:5653700. [PMID: 34659635 DOI: 10.1155/2021/5653700] [Reference Citation Analysis]
5 Simon TG, Chan AT. Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma. Clin Liver Dis 2020;24:549-76. [PMID: 33012445 DOI: 10.1016/j.cld.2020.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Testino G, Vignoli T, Patussi V, Allosio P, Amendola MF, Aricò S, Baselice A, Balbinot P, Campanile V, Fanucchi T, Greco G, Macciò L, Meneguzzi C, Mioni D, Palmieri VO, Parisi M, Renzetti D, Rossin R, Gandin C, Bottaro LC, Bernardi M, Addolorato G, Lungaro L, Zoli G, Scafato E, Caputo F. Alcohol-Related Liver Disease in the Covid-19 Era: Position Paper of the Italian Society on Alcohol (SIA). Dig Dis Sci 2021. [PMID: 34142284 DOI: 10.1007/s10620-021-07006-1] [Reference Citation Analysis]
7 Kim Y, Reddy S, Mouchli M, Summey R, Walsh C, Mir A, Bierle L, Rubio M. Gender-Specific Risk Factors Contributing to Mortality in Patients Hospitalized With Alcoholic Cirrhosis. Cureus 2021;13:e16271. [PMID: 34377607 DOI: 10.7759/cureus.16271] [Reference Citation Analysis]
8 Violi F, Loffredo L, Pastori D. Anticoagulation in patients with advanced liver disease: an open issue. Intern Emerg Med 2021;16:61-71. [PMID: 33073317 DOI: 10.1007/s11739-020-02526-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Klindt C, Reich M, Hellwig B, Stindt J, Rahnenführer J, Hengstler JG, Köhrer K, Schoonjans K, Häussinger D, Keitel V. The G Protein-Coupled Bile Acid Receptor TGR5 (Gpbar1) Modulates Endothelin-1 Signaling in Liver. Cells 2019;8:E1467. [PMID: 31752395 DOI: 10.3390/cells8111467] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
10 Pose E, Pera G, Torán P, Gratacós-Ginès J, Avitabile E, Expósito C, Díaz A, Graupera I, Rubio AB, Ginès P, Fabrellas N, Caballeria L. Interaction between metabolic syndrome and alcohol consumption, risk factors of liver fibrosis: A population-based study. Liver Int 2021;41:1556-64. [PMID: 33595176 DOI: 10.1111/liv.14830] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Fujita K, Masaki T. Serum Biomarkers of Liver Fibrosis Staging in the Era of the Concept "Compensated Advanced Chronic Liver Disease". J Clin Med 2021;10:3340. [PMID: 34362121 DOI: 10.3390/jcm10153340] [Reference Citation Analysis]
12 Durand F. Development and outcomes of the French liver allocation system. Current Opinion in Organ Transplantation 2020;25:132-8. [DOI: 10.1097/mot.0000000000000749] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Zhao R, Wu W, Zhou Z, Zheng X, Sun W, Shi Y, Yu H, Wang F, Zhao H, Sun S, Jin L, Sheng J, Shi Y. Prognostic utility of novel biomarkers in acute-on-chronic liver failure (ACLF) associated with hepatitis B: A multicenter prospective study. Hepatol Res 2019;49:42-50. [PMID: 30246902 DOI: 10.1111/hepr.13251] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
14 Ruiz-Extremera Á, Díaz-Alcázar MDM, Muñoz-Gámez JA, Cabrera-Lafuente M, Martín E, Arias-Llorente RP, Carretero P, Gallo-Vallejo JL, Romero-Narbona F, Salmerón-Ruiz MA, Alonso-Diaz C, Maese-Heredia R, Cerrillos L, Fernández-Alonso AM, Camarena C, Aguayo J, Sánchez-Forte M, Rodríguez-Maresca M, Pérez-Rivilla A, Quiles-Pérez R, Muñoz de Rueda P, Expósito-Ruiz M, García F, García F, Salmerón J. Seroprevalence and epidemiology of hepatitis B and C viruses in pregnant women in Spain. Risk factors for vertical transmission. PLoS One 2020;15:e0233528. [PMID: 32437468 DOI: 10.1371/journal.pone.0233528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Du S, Yang JZ, Chen J, Zhou WG, Sun YY. Comparisons of recurrence-free survival and overall survival between microwave versus radiofrequency ablation treatment for hepatocellular carcinoma: A multiple centers retrospective cohort study with propensity score matching. PLoS One 2020;15:e0227242. [PMID: 31918433 DOI: 10.1371/journal.pone.0227242] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
16 Buechler C, Aslanidis C. Role of lipids in pathophysiology, diagnosis and therapy of hepatocellular carcinoma.Biochim Biophys Acta Mol Cell Biol Lipids. 2020;1865:158658. [PMID: 32058031 DOI: 10.1016/j.bbalip.2020.158658] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
17 Lonardo A, Leoni S, Alswat KA, Fouad Y. History of Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E5888. [PMID: 32824337 DOI: 10.3390/ijms21165888] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
18 Lazarus JV, Cortez-Pinto H, Anstee QM. Reply to: "Caveats for the implementation of global strategies against non-alcoholic fatty liver disease". J Hepatol 2020;73:221-2. [PMID: 32280051 DOI: 10.1016/j.jhep.2020.03.017] [Reference Citation Analysis]
19 Siddiqui ATS, Parkash O, Hashmi SA. Malnutrition and liver disease in a developing country. World J Gastroenterol 2021; 27(30): 4985-4998 [PMID: 34497430 DOI: 10.3748/wjg.v27.i30.4985] [Reference Citation Analysis]
20 Teschke R, Eickhoff A, Brown AC, Neuman MG, Schulze J. Diagnostic Biomarkers in Liver Injury by Drugs, Herbs, and Alcohol: Tricky Dilemma after EMA Correctly and Officially Retracted Letter of Support. Int J Mol Sci 2019;21:E212. [PMID: 31892250 DOI: 10.3390/ijms21010212] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
21 Adiamah A, Ban L, Hammond J, Jepsen P, West J, Humes DJ. Mortality After Extrahepatic Gastrointestinal and Abdominal Wall Surgery in Patients With Alcoholic Liver Disease: A Systematic Review and Meta-Analysis. Alcohol Alcohol 2020;55:497-511. [PMID: 32558895 DOI: 10.1093/alcalc/agaa043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Wakabayashi SI, Joshita S, Kimura K, Motoki H, Kobayashi H, Yamashita Y, Sugiura A, Yamazaki T, Kuwahara K, Umemura T. Protocol: Prospective observational study investigating the prevalence and clinical outcome of portopulmonary hypertension in Japanese patients with chronic liver disease. PLoS One 2021;16:e0249435. [PMID: 33793649 DOI: 10.1371/journal.pone.0249435] [Reference Citation Analysis]
23 Schneider CV, Fromme M, Schneider KM, Bruns T, Strnad P. Mortality in Patients With Genetic and Environmental Risk of Liver Disease. Am J Gastroenterol 2021;116:1741-5. [PMID: 34131090 DOI: 10.14309/ajg.0000000000001326] [Reference Citation Analysis]
24 Kim SE, Park JW, Kim HS, Jang MK, Suk KT, Kim DJ. The Role of Gut Dysbiosis in Acute-on-Chronic Liver Failure. Int J Mol Sci 2021;22:11680. [PMID: 34769109 DOI: 10.3390/ijms222111680] [Reference Citation Analysis]
25 Pose E, Torrents A, Reverter E, Perez-Campuzano V, Campos-Varela I, Avitabile E, Gratacós-Ginès J, Castellote J, Castells L, Colmenero J, Tort J, Ginès P, Crespo G. A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement. J Hepatol 2021;75:275-83. [PMID: 33746085 DOI: 10.1016/j.jhep.2021.02.033] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Møller S, Kimer N, Barløse M, Bendtsen F. Pathophysiological-based treatments of complications of cirrhosis. Scand J Gastroenterol 2020;55:383-94. [PMID: 32233873 DOI: 10.1080/00365521.2020.1744709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Ciabiada-Bryła B, Maniecka-Bryła I, Paciej-Gołębiowska P. Years of life lost due to alcohol-related mortality: A nationwide population study in Poland, 1999-2017. Drug Alcohol Depend 2021;227:108990. [PMID: 34482047 DOI: 10.1016/j.drugalcdep.2021.108990] [Reference Citation Analysis]
28 Lyra AC, de Almeida LMC, Mise YF, Cavalcante LN. Epidemiological profile of alcoholic liver disease hospital admissions in a Latin American country over a 10-year period. World J Hepatol 2020; 12(5): 230-238 [PMID: 32547690 DOI: 10.4254/wjh.v12.i5.230] [Reference Citation Analysis]
29 Meyer F, Bannert K, Wiese M, Esau S, Sautter LF, Ehlers L, Aghdassi AA, Metges CC, Garbe LA, Jaster R, Lerch MM, Lamprecht G, Valentini L. Molecular Mechanism Contributing to Malnutrition and Sarcopenia in Patients with Liver Cirrhosis. Int J Mol Sci 2020;21:E5357. [PMID: 32731496 DOI: 10.3390/ijms21155357] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
30 Luo Y, Ye J, Wei J, Zhang J, Li Y. Long non‑coding RNA‑based risk scoring system predicts prognosis of alcohol‑related hepatocellular carcinoma. Mol Med Rep 2020;22:997-1007. [PMID: 32468063 DOI: 10.3892/mmr.2020.11179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Duffell E, Cortez-Pinto H, Simonova M, Dalgard O, Dahl EH, de Martel C, Mozalevskis A, Buti M, Pavlova S, Hadzhilova T, Simões C, Katzarov K, Mardh O. Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and C. J Viral Hepat 2021;28:1177-89. [PMID: 34003542 DOI: 10.1111/jvh.13545] [Reference Citation Analysis]
32 Melaram R. Environmental Risk Factors Implicated in Liver Disease: A Mini-Review. Front Public Health 2021;9:683719. [PMID: 34249849 DOI: 10.3389/fpubh.2021.683719] [Reference Citation Analysis]
33 Engelmann C, Martino VD, Kerbert AJC, Weil-Verhoeven D, Aehling NF, Herber A, Thévenot T, Berg T. The Current Status of Granulocyte-Colony Stimulating Factor to Treat Acute-on-Chronic Liver Failure. Semin Liver Dis 2021;41:298-307. [PMID: 33992029 DOI: 10.1055/s-0041-1723034] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Avila MA, Dufour JF, Gerbes AL, Zoulim F, Bataller R, Burra P, Cortez-Pinto H, Gao B, Gilmore I, Mathurin P, Moreno C, Poznyak V, Schnabl B, Szabo G, Thiele M, Thursz MR. Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. Gut 2020;69:764-80. [PMID: 31879281 DOI: 10.1136/gutjnl-2019-319720] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
35 Campana L, Esser H, Huch M, Forbes S. Liver regeneration and inflammation: from fundamental science to clinical applications. Nat Rev Mol Cell Biol 2021;22:608-24. [PMID: 34079104 DOI: 10.1038/s41580-021-00373-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Dillon JF, Miller MH, Robinson EM, Hapca A, Rezaeihemami M, Weatherburn C, Mcintyre PG, Bartlett B, Donnan PT, Boyd KA, Dow E. Intelligent liver function testing (iLFT): A trial of automated diagnosis and staging of liver disease in primary care. Journal of Hepatology 2019;71:699-706. [DOI: 10.1016/j.jhep.2019.05.033] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
37 Marti-Aguado D, Rodríguez-Ortega A, Alberich-Bayarri A, Marti-Bonmati L. Magnetic Resonance imaging analysis of liver fibrosis and inflammation: overwhelming gray zones restrict clinical use. Abdom Radiol (NY) 2020;45:3557-68. [PMID: 32857259 DOI: 10.1007/s00261-020-02713-1] [Reference Citation Analysis]
38 Alemany-Pagès M, Moura-Ramos M, Araújo S, Macedo MP, Ribeiro RT, do Ó D, Ramalho-Santos J, Azul AM. Insights from qualitative research on NAFLD awareness with a cohort of T2DM patients: time to go public with insulin resistance? BMC Public Health 2020;20:1142. [PMID: 32690054 DOI: 10.1186/s12889-020-09249-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
39 Yan T, Liu B, Li F, Wu B, Xiao F, He B, Jia Y. Schizandrin ameliorates behavioral disorders in hepatic injury mice via regulation of oxidative stress and neuroinflammation. Immunopharmacol Immunotoxicol 2021;43:212-22. [PMID: 33588680 DOI: 10.1080/08923973.2021.1879847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Li L, Zheng W, Wang C, Qi J, Li H. Mogroside V Protects against Hepatic Steatosis in Mice on a High-Fat Diet and LO2 Cells Treated with Free Fatty Acids via AMPK Activation. Evid Based Complement Alternat Med 2020;2020:7826874. [PMID: 32419825 DOI: 10.1155/2020/7826874] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Loosen SH, Kostev K, Keitel V, Tacke F, Roderburg C, Luedde T. An elevated FIB-4 score predicts liver cancer development: A longitudinal analysis from 29,999 patients with NAFLD. J Hepatol 2021:S0168-8278(21)02028-6. [PMID: 34520785 DOI: 10.1016/j.jhep.2021.08.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Wahlin S, Andersson J. Liver health literacy and social stigma of liver disease: A general population e-survey. Clin Res Hepatol Gastroenterol 2021;45:101750. [PMID: 34175458 DOI: 10.1016/j.clinre.2021.101750] [Reference Citation Analysis]
43 McKay A, Pantoja C, Hall R, Matthews S, Spalding P, Banerjee R. Patient understanding and experience of non-invasive imaging diagnostic techniques and the liver patient pathway. J Patient Rep Outcomes 2021;5:89. [PMID: 34508298 DOI: 10.1186/s41687-021-00363-5] [Reference Citation Analysis]
44 Liu Z, Shi O, Zhang T, Jin L, Chen X. Disease burden of viral hepatitis A, B, C and E: A systematic analysis. J Viral Hepat 2020;27:1284-96. [PMID: 32741034 DOI: 10.1111/jvh.13371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
45 Méndez-Sánchez N, Valencia-Rodríguez A. Caveats for the implementation of global strategies against non-alcoholic fatty liver disease. J Hepatol 2020;73:220. [PMID: 32229039 DOI: 10.1016/j.jhep.2020.02.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
46 Tan HK, Yates E, Lilly K, Dhanda AD. Oxidative stress in alcohol-related liver disease. World J Hepatol 2020; 12(7): 332-349 [PMID: 32821333 DOI: 10.4254/wjh.v12.i7.332] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
47 Chen Z, Peng X, Tan L, Zhai G, Chen G, Gan T, Li J. EBV as a potential risk factor for hepatobiliary system cancer: A meta-analysis with 918 cases. Pathology - Research and Practice 2019;215:278-85. [DOI: 10.1016/j.prp.2018.10.037] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
48 Aishwarya V, Solaipriya S, Sivaramakrishnan V. Role of ellagic acid for the prevention and treatment of liver diseases. Phytother Res 2021;35:2925-44. [PMID: 33368795 DOI: 10.1002/ptr.7001] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Vitale A, Svegliati-Baroni G, Ortolani A, Cucco M, Dalla Riva GV, Giannini EG, Piscaglia F, Rapaccini G, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Foschi FG, Missale G, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Pelizzaro F, Ramirez Morales R, Cillo U, Trevisani F, Miele L, Marchesini G, Farinati F; Italian Liver Cancer (ITA.LI.CA) group. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database. Gut 2021:gutjnl-2021-324915. [PMID: 34933916 DOI: 10.1136/gutjnl-2021-324915] [Reference Citation Analysis]
50 Durand F, Pavesi M, Cheung R. Liver transplantation for non-alcoholic steatohepatitis in Europe: Where do we stand? J Hepatol 2019;71:240-2. [PMID: 31229271 DOI: 10.1016/j.jhep.2019.05.018] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
51 Hadefi A, Degré D, Trépo E, Moreno C. Noninvasive diagnosis in alcohol-related liver disease. Health Sci Rep 2020;3:e146. [PMID: 32166191 DOI: 10.1002/hsr2.146] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
52 Campos-Varela I, Dodge JL, Berenguer M, Adam R, Samuel D, Di Benedetto F, Karam V, Belli LS, Duvoux C, Terrault NA. Temporal Trends and Outcomes in Liver Transplantation for Recipients With HIV Infection in Europe and United States. Transplantation 2020;104:2078-86. [PMID: 32969987 DOI: 10.1097/TP.0000000000003107] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
53 Schiavon LL, Ejima FH, Menezes MR, Bittencourt PL, Moreira AM, Farias AQ, Chagas AL, Assis AM, Mattos ÂZ, Salomão BC, Terra C, Martins FPB, Carnevale FC, Rezende GFDM, Paulo GA, Pereira GHS, Leal Filho JMDM, Meneses J, Costa LSND, Carneiro MV, Álvares-DA-Silva MR, Soares MVA, Pereira OI, Ximenes RO, Durante RFS, Ferreira VA, Lima VM; Members of the Pannel of the 1st Joint Meeting of the SBH, SOBED and SOBRICE. RECOMMENDATIONS FOR INVASIVE PROCEDURES IN PATIENTS WITH DISEASES OF THE LIVER AND BILIARY TRACT: REPORT OF A JOINT MEETING OF THE BRAZILIAN SOCIETY OF HEPATOLOGY (SBH), BRAZILIAN SOCIETY OF DIGESTIVE ENDOSCOPY (SOBED) AND BRAZILIAN SOCIETY OF INTERVENTIONAL RADIOLOGY AND ENDOVASCULAR SURGERY (SOBRICE). Arq Gastroenterol 2019;56:213-31. [PMID: 31460590 DOI: 10.1590/S0004-2803.201900000-42] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
54 Marjot T, Moon AM, Cook JA, Abd-Elsalam S, Aloman C, Armstrong MJ, Pose E, Brenner EJ, Cargill T, Catana MA, Dhanasekaran R, Eshraghian A, García-Juárez I, Gill US, Jones PD, Kennedy J, Marshall A, Matthews C, Mells G, Mercer C, Perumalswami PV, Avitabile E, Qi X, Su F, Ufere NN, Wong YJ, Zheng MH, Barnes E, Barritt AS 4th, Webb GJ. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. J Hepatol 2021;74:567-77. [PMID: 33035628 DOI: 10.1016/j.jhep.2020.09.024] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 34.5] [Reference Citation Analysis]
55 D'Amico G, Bataller R. Need for surveillance of hepatocellular carcinoma in patients with alcoholic cirrhosis. J Hepatol 2018;69:1219-20. [PMID: 30318321 DOI: 10.1016/j.jhep.2018.09.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
56 Königshofer P, Brusilovskaya K, Schwabl P, Reiberger T. Animal models of portal hypertension. Biochim Biophys Acta Mol Basis Dis 2019;1865:1019-30. [PMID: 30055295 DOI: 10.1016/j.bbadis.2018.07.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Jepsen P, Younossi ZM. The global burden of cirrhosis: A review of disability-adjusted life-years lost and unmet needs. J Hepatol 2021;75 Suppl 1:S3-S13. [PMID: 34039490 DOI: 10.1016/j.jhep.2020.11.042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
58 Paternostro R, Becker J, Hofer BS, Panagl V, Schiffke H, Simbrunner B, Semmler G, Schwabl P, Scheiner B, Bucsics T, Bauer D, Binter T, Trauner M, Mandorfer M, Reiberger T. The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices. Dig Liver Dis 2021:S1590-8658(21)00778-7. [PMID: 34799282 DOI: 10.1016/j.dld.2021.09.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Walker JL, Grint DJ, Strongman H, Eggo RM, Peppa M, Minassian C, Mansfield KE, Rentsch CT, Douglas IJ, Mathur R, Wong AYS, Quint JK, Andrews N, Bernal JL, Scott JA, Ramsay M, Smeeth L, McDonald HI. UK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records. BMC Public Health 2021;21:484. [PMID: 33706738 DOI: 10.1186/s12889-021-10427-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
60 Minosse C, Gruber CEM, Rueca M, Taibi C, Zaccarelli M, Grilli E, Montalbano M, Capobianchi MR, Antinori A, D'Offizi G, McPhee F, Garbuglia AR. Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs. Viruses 2021;13:1151. [PMID: 34208646 DOI: 10.3390/v13061151] [Reference Citation Analysis]
61 Myers S, Neyroud-Caspar I, Spahr L, Gkouvatsos K, Fournier E, Giostra E, Magini G, Frossard JL, Bascaron ME, Vernaz N, Zampaglione L, Negro F, Goossens N. NAFLD and MAFLD as emerging causes of HCC: A populational study. JHEP Rep 2021;3:100231. [PMID: 33748726 DOI: 10.1016/j.jhepr.2021.100231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
62 Matyas C, Haskó G, Liaudet L, Trojnar E, Pacher P. Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications. Nat Rev Cardiol 2021;18:117-35. [PMID: 32999450 DOI: 10.1038/s41569-020-0433-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
63 Xiong Y, Huang J. Anti-malarial drug: the emerging role of artemisinin and its derivatives in liver disease treatment. Chin Med 2021;16:80. [PMID: 34407830 DOI: 10.1186/s13020-021-00489-0] [Reference Citation Analysis]
64 Pluta KD, Samluk A, Wencel A, Zakrzewska KE, Gora M, Burzynska B, Ciezkowska M, Motyl J, Pijanowska DG. Genetically modified C3A cells with restored urea cycle for improved bioartificial liver. Biocybernetics and Biomedical Engineering 2020;40:378-87. [DOI: 10.1016/j.bbe.2019.12.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
65 Akbulut S, Gunes G, Saritas H, Aslan B, Karipkiz Y, Demyati K, Gungor S, Yilmaz S. Differences in parents of pediatric liver transplantation and chronic liver disease patients. World J Clin Cases 2020; 8(11): 2162-2172 [PMID: 32548146 DOI: 10.12998/wjcc.v8.i11.2162] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
66 Glyn-Owen K, Böhning D, Parkes J, Roderick P, Buchanan R. The combined effect of alcohol and body mass index on risk of chronic liver disease: A systematic review and meta-analysis of cohort studies. Liver Int 2021;41:1216-26. [PMID: 33283434 DOI: 10.1111/liv.14754] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
67 Manns MP, Burra P, Sargent J, Horton R, Karlsen TH. The Lancet-EASL Commission on liver diseases in Europe: overcoming unmet needs, stigma, and inequities. Lancet 2018;392:621-2. [PMID: 30060999 DOI: 10.1016/S0140-6736(18)31734-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
68 Ntandja Wandji LC, Gnemmi V, Mathurin P, Louvet A. Combined alcoholic and non-alcoholic steatohepatitis. JHEP Rep 2020;2:100101. [PMID: 32514497 DOI: 10.1016/j.jhepr.2020.100101] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
69 Ghallab A, Myllys M, Holland CH, Zaza A, Murad W, Hassan R, Ahmed YA, Abbas T, Abdelrahim EA, Schneider KM, Matz-Soja M, Reinders J, Gebhardt R, Berres ML, Hatting M, Drasdo D, Saez-Rodriguez J, Trautwein C, Hengstler JG. Influence of Liver Fibrosis on Lobular Zonation. Cells 2019;8:E1556. [PMID: 31810365 DOI: 10.3390/cells8121556] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
70 Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA, Ouatu A, Floria M. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD).J Diabetes Res. 2020;2020:3920196. [PMID: 32832560 DOI: 10.1155/2020/3920196] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
71 Atkins JL, Pilling LC, Masoli JAH, Kuo CL, Shearman JD, Adams PC, Melzer D. Association of Hemochromatosis HFE p.C282Y Homozygosity With Hepatic Malignancy. JAMA 2020;324:2048-57. [PMID: 33231665 DOI: 10.1001/jama.2020.21566] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
72 Li Y, De Stefano V, Li H, Zheng K, Bai Z, Guo X, Qi X. Epidemiology of Budd-Chiari syndrome: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2019;43:468-74. [PMID: 30528513 DOI: 10.1016/j.clinre.2018.10.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
73 Han SW, Wang XJ, Cui BS, Sun H, Chen H, Ferreira D, Li S, Hamann MT. Hepatoprotective Glucosyloxybenzyl 2-Hydroxy-2-isobutylsuccinates from Pleione yunnanensis. J Nat Prod 2021;84:738-49. [PMID: 33606538 DOI: 10.1021/acs.jnatprod.0c01117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Alferink LJM, Erler NS, de Knegt RJ, Janssen HLA, Metselaar HJ, Darwish Murad S, Kiefte-de Jong JC. Adherence to a plant-based, high-fibre dietary pattern is related to regression of non-alcoholic fatty liver disease in an elderly population. Eur J Epidemiol 2020;35:1069-85. [PMID: 32323115 DOI: 10.1007/s10654-020-00627-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
75 Li LJ, Wu XY, Tan SW, Xie ZJ, Pan XM, Pan SW, Bai WR, Li HJ, Liu HL, Jiang J, Wu B. Lnc-TCL6 is a potential biomarker for early diagnosis and grade in liver-cirrhosis patients. Gastroenterol Rep (Oxf). 2019;7:434-443. [PMID: 31857905 DOI: 10.1093/gastro/goz050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
76 De Benedittis C, Bellan M, Crevola M, Boin E, Barbaglia MN, Mallela VR, Ravanini P, Ceriani E, Fangazio S, Sainaghi PP, Burlone ME, Minisini R, Pirisi M. Interplay of PNPLA3 and HSD17B13 Variants in Modulating the Risk of Hepatocellular Carcinoma among Hepatitis C Patients. Gastroenterol Res Pract 2020;2020:4216451. [PMID: 32382265 DOI: 10.1155/2020/4216451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
77 Kauppila JH, Tao W, Santoni G, von Euler-Chelpin M, Lynge E, Tryggvadóttir L, Ness-Jensen E, Romundstad P, Pukkala E, Lagergren J. Effects of Obesity Surgery on Overall and Disease-Specific Mortality in a 5-Country Population-Based Study. Gastroenterology 2019;157:119-127.e1. [PMID: 30940524 DOI: 10.1053/j.gastro.2019.03.048] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
78 Benedé-Ubieto R, Estévez-Vázquez O, Guo F, Chen C, Singh Y, Nakaya HI, Gómez Del Moral M, Lamas-Paz A, Morán L, López-Alcántara N, Reissing J, Bruns T, Avila MA, Santamaría E, Mazariegos MS, Woitok MM, Haas U, Zheng K, Juárez I, Martín-Villa JM, Asensio I, Vaquero J, Peligros MI, Argemi J, Bataller R, Ampuero J, Romero Gómez M, Trautwein C, Liedtke C, Bañares R, Cubero FJ, Nevzorova YA. An Experimental DUAL Model of Advanced Liver Damage. Hepatol Commun 2021;5:1051-68. [PMID: 34141989 DOI: 10.1002/hep4.1698] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
79 Hui Lim GE, Tang A, Ng CH, Chin YH, Lim WH, Hao Tan DJ, Yong JN, Xiao J, Wen-Min Lee C, Chan M, Chew NW, Xuan Tan EX, Siddiqui MS, Huang D, Noureddin M, Sanyal AJ, Muthiah MD. An Observational Data Meta-Analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01276-3. [PMID: 34871813 DOI: 10.1016/j.cgh.2021.11.038] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Carlessi R, Köhn-gaone J, Olynyk JK, Tirnitz-parker JEE; School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Bentley, WA, Australia, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Bentley, WA, Australia, Fiona Stanley and Fremantle Hospitals, Fremantle and Murdoch, WA, Australia, School of Health and Medical Sciences, Edith Cowan University, Joondalup, WA, Australia, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Bentley, WA, Australia, Centre for Cell Therapy and Regenerative Medicine, School of Biomedical Sciences, The University of Western Australia, Crawley WA, Australia. Mouse Models of Hepatocellular Carcinoma. In: Tirnitz-parker JE, editor. Hepatocellular Carcinoma. Codon Publications; 2019. pp. 69-94. [DOI: 10.15586/hepatocellularcarcinoma.2019.ch4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Axley PD, Richardson CT, Singal AK. Epidemiology of Alcohol Consumption and Societal Burden of Alcoholism and Alcoholic Liver Disease. Clin Liver Dis 2019;23:39-50. [PMID: 30454831 DOI: 10.1016/j.cld.2018.09.011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 10.7] [Reference Citation Analysis]
82 Pocha C, Xie C. Hepatocellular carcinoma in alcoholic and non-alcoholic fatty liver disease-one of a kind or two different enemies? Transl Gastroenterol Hepatol 2019;4:72. [PMID: 31728429 DOI: 10.21037/tgh.2019.09.01] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
83 Konturek PC, Harsch IA, Konturek K, Schink M, Konturek T, Neurath MF, Zopf Y. Gut⁻Liver Axis: How Do Gut Bacteria Influence the Liver? Med Sci (Basel) 2018;6:E79. [PMID: 30227645 DOI: 10.3390/medsci6030079] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
84 Vorobioff JD, Contreras F, Tanno F, Hernández L, Bessone F, Colombato L, Adi J, Fassio E, Felgueres M, Fernández G, Gaite L, Gibelli D, Darrichon HG, Lafage M, Lombardo D, López S, Mateo A, Mendizábal M, Pecoraro J, Ruf A, Ruiz P, Severini J, Stieben T, Sixto M, Zárate F, Barraza SB, Sierra ID, Pacheco VR, Roblero JP, Rojas JO, González PR, Rodríguez DSM, Sierralta A, Manchego AU, Valdes E, Yaquich P, Wolff R, Valdivia FB, Gallegos RC, Galloso R, Marcelo JS, Montes P, Tenorio L, Veramendi I, Alava E, Armijos X, Benalcazar G, Carrera E, Pazmiño GF, Díaz EM, Garassini M, Marrero RP, Infante M, Suárez DP, Gutiérrez JC, Reyes CMV, Serrano YM, Hernández RH, Martínez OM, González TP, Andara MT, Hernández MS, Gerona S, García I, Tijera F, López EP, Torres K, Garzón M. A Latin American survey on demographic aspects of hospitalized, decompensated cirrhotic patients and the resources for their management. Ann Hepatol 2020;19:396-403. [PMID: 32418749 DOI: 10.1016/j.aohep.2020.03.007] [Reference Citation Analysis]
85 Zheng K, Yoshida EM, Tacke F, Li Y, Guo X, Qi X. Risk of Stroke in Liver Cirrhosis: A Systematic Review and Meta-Analysis. Journal of Clinical Gastroenterology 2020;54:96-105. [DOI: 10.1097/mcg.0000000000001201] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
86 Li W, Kemos P, Salciccioli JD, Marshall DC, Shalhoub J, Alazawi W. Socioeconomic Factors Associated With Liver-Related Mortality From 1985 to 2015 in 36 Developed Countries. Clin Gastroenterol Hepatol 2021;19:1698-1707.e13. [PMID: 32835839 DOI: 10.1016/j.cgh.2020.08.047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
87 Asrani SK, Mellinger J, Arab JP, Shah VH. Reducing the Global Burden of Alcohol-Associated Liver Disease: A Blueprint for Action. Hepatology 2021;73:2039-50. [PMID: 32986883 DOI: 10.1002/hep.31583] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
88 Silva JM, Silva MJ, Calinas F, Nogueira PJ. Burden of Liver Cirrhosis in Portugal between 2010 and 2017. GE Port J Gastroenterol 2021;28:153-61. [PMID: 34056037 DOI: 10.1159/000510729] [Reference Citation Analysis]
89 Solà E, Pose E, Campion D, Piano S, Roux O, Simon-Talero M, Uschner F, de Wit K, Zaccherini G, Alessandria C, Beuers U, Caraceni P, Francoz C, Mookerjee RP, Trebicka J, Vargas V, Serra M, Torres F, Montagnese S, Krag A, Hernaez R, Korenjak M, Watson H, Abraldes JG, Kamath PS, Ginès P; LiverHope Consortium Investigators. Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. J Hepatol 2021;74:200-19. [PMID: 32896580 DOI: 10.1016/j.jhep.2020.08.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
90 Kautz A, Dorner R, Antoni C, Ebert M, Teufel A. Self-testing for liver disease – response to an online liver test questionnaire. Scandinavian Journal of Gastroenterology 2020;55:67-73. [DOI: 10.1080/00365521.2019.1699600] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
91 Tesfaye BT, Feyissa TM, Workneh AB, Gudina EK, Yizengaw MA. Chronic Liver Disease in Ethiopia with a Particular Focus on the Etiological Spectrums: A Systematic Review and Meta-Analysis of Observational Studies. Can J Gastroenterol Hepatol 2021;2021:8740157. [PMID: 34858892 DOI: 10.1155/2021/8740157] [Reference Citation Analysis]
92 Guixé-muntet S, Zhu C, Xie W, Gracia-sancho J. Novel therapeutics for portal hypertension and fibrosis in chronic liver disease. Pharmacology & Therapeutics 2020;215:107626. [DOI: 10.1016/j.pharmthera.2020.107626] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
93 Connolly C, Stättner S, Niederwieser T, Primavesi F. Systematic review on peri-operative lactate measurements to predict outcomes in patients undergoing liver resection. J Hepatobiliary Pancreat Sci 2020;27:359-70. [PMID: 32065510 DOI: 10.1002/jhbp.727] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
94 Kang SH, Kim MY. Outcomes of Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir in Mongolian Population: Successes and Challenges Facing Scale-up of Care. Clin Mol Hepatol 2021;27:100-2. [PMID: 33317234 DOI: 10.3350/cmh.2020.0312] [Reference Citation Analysis]
95 Wang X, Xie W, Gan S, Wang T, Chen X, Su D, Sun J, Lin J, Wu F, Xu P, Miao C, Yan M, Zhu S, Zhai B, Sun Y, Yu W, Tian J. Effects of general anesthesia versus local anesthesia in primary hepatocellular carcinoma patients presenting for thermal ablation surgery: a multiple center retrospective cohort study with propensity score matching. Ann Transl Med 2020;8:277. [PMID: 32355721 DOI: 10.21037/atm.2020.03.88] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
96 Arias-Loste MT, Iruzubieta P, Crespo J. Paediatric non-alcoholic fatty liver disease: a more complex disease than in the adulthood? Hepatobiliary Surg Nutr 2019;8:270-3. [PMID: 31245411 DOI: 10.21037/hbsn.2018.12.16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
97 Simbrunner B, Mandorfer M, Trauner M, Reiberger T. Gut-liver axis signaling in portal hypertension. World J Gastroenterol 2019; 25(39): 5897-5917 [PMID: 31660028 DOI: 10.3748/wjg.v25.i39.5897] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 19] [Article Influence: 8.7] [Reference Citation Analysis]
98 Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 2022;399:61-116. [PMID: 34863359 DOI: 10.1016/S0140-6736(21)01701-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Yang L, Wei C, Li Y, He X, He M. miR-224 is an early-stage biomarker of hepatocellular carcinoma with miR-224 and miR-125b as prognostic biomarkers. Biomark Med 2020;14:1485-500. [PMID: 33155836 DOI: 10.2217/bmm-2020-0099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
100 Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, Mathurin P, Mueller S, Szabo G, Tsukamoto H. Alcoholic liver disease. Nat Rev Dis Primers. 2018;4:16. [PMID: 30115921 DOI: 10.1038/s41572-018-0014-7] [Cited by in Crossref: 191] [Cited by in F6Publishing: 195] [Article Influence: 47.8] [Reference Citation Analysis]
101 Durazzo M, Ponzo E, Bonetto S, Fagoonee S, Pellicano R. Liver diseases in the elderly. Minerva Med 2019;110. [DOI: 10.23736/s0026-4806.18.05858-5] [Cited by in Crossref: 8] [Article Influence: 2.7] [Reference Citation Analysis]
102 Cortesi PA, Barca R, Giudicatti G, Mossini S, Ciaccio A, Iannazzo S, Micale M, Cesana G, Mantovani LG. Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era. Aliment Pharmacol Ther 2019;49:1126-33. [PMID: 30843268 DOI: 10.1111/apt.15201] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
103 Kurniawan DW, Jajoriya AK, Dhawan G, Mishra D, Argemi J, Bataller R, Storm G, Mishra DP, Prakash J, Bansal R. Therapeutic inhibition of spleen tyrosine kinase in inflammatory macrophages using PLGA nanoparticles for the treatment of non-alcoholic steatohepatitis. J Control Release. 2018;288:227-238. [PMID: 30219279 DOI: 10.1016/j.jconrel.2018.09.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
104 Bosetti C, Traini E, Alam T, Allen CA, Carreras G, Compton K, Fitzmaurice C, Force LM, Gallus S, Gorini G, Harvey JD, Kocarnik JM, La Vecchia C, Lugo A, Naghavi M, Pennini A, Piccinelli C, Ronfani L, Xu R, Monasta L. National burden of cancer in Italy, 1990-2017: a systematic analysis for the global burden of disease study 2017. Sci Rep 2020;10:22099. [PMID: 33328623 DOI: 10.1038/s41598-020-79176-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
105 Hu D, Huang S, Ding Y, Zhao X, Zhang W, Chen H, Wang J. Specnuezhenide reduces carbon tetrachloride-induced liver injury in mice through inhibition of oxidative stress and hepatocyte apoptosis. J Pharm Pharmacol 2021:rgab164. [PMID: 34923584 DOI: 10.1093/jpp/rgab164] [Reference Citation Analysis]
106 Alferink LJM, Radjabzadeh D, Erler NS, Vojinovic D, Medina-Gomez C, Uitterlinden AG, de Knegt RJ, Amin N, Ikram MA, Janssen HLA, Kiefte-de Jong JC, Metselaar HJ, van Duijn CM, Kraaij R, Darwish Murad S. Microbiomics, Metabolomics, Predicted Metagenomics, and Hepatic Steatosis in a Population-Based Study of 1,355 Adults.Hepatology. 2021;73:968-982. [PMID: 32530501 DOI: 10.1002/hep.31417] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
107 Xiang L, Shao Y, Chen Y. Mitochondrial dysfunction and mitochondrion-targeted therapeutics in liver diseases. J Drug Target 2021;:1-14. [PMID: 33788656 DOI: 10.1080/1061186X.2021.1909051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
108 Zhou M, Deng Y, Liu M, Liao L, Dai X, Guo C, Zhao X, He L, Peng C, Li Y. The pharmacological activity of berberine, a review for liver protection. Eur J Pharmacol 2021;890:173655. [PMID: 33068590 DOI: 10.1016/j.ejphar.2020.173655] [Reference Citation Analysis]
109 De Smet V, Eysackers N, Merens V, Kazemzadeh Dastjerd M, Halder G, Verhulst S, Mannaerts I, van Grunsven LA. Initiation of hepatic stellate cell activation extends into chronic liver disease. Cell Death Dis 2021;12:1110. [PMID: 34839349 DOI: 10.1038/s41419-021-04377-1] [Reference Citation Analysis]
110 Acharya C, Bajaj JS. Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease. Gastroenterology 2021;160:556-72. [PMID: 33253686 DOI: 10.1053/j.gastro.2020.10.056] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
111 Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. Hepatology. 2020;72:1605-1616. [PMID: 32043613 DOI: 10.1002/hep.31173] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 34.5] [Reference Citation Analysis]
112 Xu L, Wang Z, Yin C, Pan F, Shi T, Tian Y. Long noncoding RNA LINC02580 suppresses the invasion-metastasis cascade in hepatocellular carcinoma by targeting SRSF1. Biochem Biophys Res Commun 2020;533:685-91. [PMID: 33168192 DOI: 10.1016/j.bbrc.2020.10.061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
113 Ghallab A, Seddek A. PPARG as therapeutic target for antifibrotic therapy. EXCLI J 2020;19:227-9. [PMID: 32256268 DOI: 10.17179/excli2020-1136] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
114 Liu Z, Mao X, Jiang Y, Cai N, Jin L, Zhang T, Chen X. Changing trends in the disease burden of primary liver cancer caused by specific etiologies in China. Cancer Med 2019;8:5787-99. [PMID: 31385465 DOI: 10.1002/cam4.2477] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
115 Godfrey EL, Stribling R, Rana A. Liver Transplantation for Alcoholic Liver Disease: An Update. Clin Liver Dis 2019;23:127-39. [PMID: 30454827 DOI: 10.1016/j.cld.2018.09.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
116 Skladany L, Molcan P, Vnencakova J, Vrbova P, Kukla M, Laffers L, Koller T. Frailty in Nonalcoholic Fatty Liver Cirrhosis: A Comparison with Alcoholic Cirrhosis, Risk Patterns, and Impact on Prognosis. Can J Gastroenterol Hepatol 2021;2021:5576531. [PMID: 34095016 DOI: 10.1155/2021/5576531] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Catucci D, Obmann VC, Berzigotti A, Gräni C, Guensch DP, Fischer K, Ebner L, Heverhagen JT, Christe A, Huber AT. Noninvasive assessment of clinically significant portal hypertension using ΔT1 of the liver and spleen and ECV of the spleen on routine Gd-EOB-DTPA liver MRI. Eur J Radiol 2021;144:109958. [PMID: 34571458 DOI: 10.1016/j.ejrad.2021.109958] [Reference Citation Analysis]
118 Ullah U, Badshah H, Malik Z, Uddin Z, Alam M, Sarwar S, Aman A, Khan AU, Shah FA. Hepatoprotective effects of melatonin and celecoxib against ethanol-induced hepatotoxicity in rats. Immunopharmacol Immunotoxicol 2020;42:255-63. [PMID: 32249710 DOI: 10.1080/08923973.2020.1746802] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
119 Mourad M, Lebossé F, Merle P, Levrero M, Antonini T, Lesurtel M, Ducerf C, Zoulim F, Mabrut JY, Mohkam K. External validation of the French alpha-fetoprotein model for hepatocellular carcinoma liver transplantation in a recent unicentric cohort - a retrospective study. Transpl Int 2021;34:535-45. [PMID: 33449394 DOI: 10.1111/tri.13819] [Reference Citation Analysis]
120 De Vincentis A, Tavaglione F, Jamialahmadi O, Picardi A, Antonelli Incalzi R, Valenti L, Romeo S, Vespasiani-Gentilucci U. A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00595-4. [PMID: 34091049 DOI: 10.1016/j.cgh.2021.05.056] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
121 Azzaroli F, Mazzella G, Marchesini G, Brodosi L, Petroni ML. Fatty liver in pregnancy: a narrative review of two distinct conditions. Expert Rev Gastroenterol Hepatol 2020;14:127-35. [PMID: 31928239 DOI: 10.1080/17474124.2020.1715210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
122 Seitz HK, Neuman MG. The History of Alcoholic Liver Disease: From an Unrecognized Disease to One of the Most Frequent Diseases in Hepatology. J Clin Med 2021;10:858. [PMID: 33669694 DOI: 10.3390/jcm10040858] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
123 Caputo F, Domenicali M, Bernardi M. Diagnosis and Treatment of Alcohol Use Disorder in Patients With End-Stage Alcoholic Liver Disease. Hepatology 2019;70:410-7. [PMID: 30471136 DOI: 10.1002/hep.30358] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
124 Hatzakis A, Lazarus JV, Cholongitas E, Baptista-Leite R, Boucher C, Busoi CS, Deuffic-Burban S, Chhatwal J, Esmat G, Hutchinson S, Malliori MM, Maticic M, Mozalevskis A, Negro F, Papandreou GA, Papatheodoridis GV, Peck-Radosavljevic M, Razavi H, Reic T, Schatz E, Tozun N, Younossi Z, Manns MP. Securing sustainable funding for viral hepatitis elimination plans. Liver Int. 2020;40:260-270. [PMID: 31808281 DOI: 10.1111/liv.14282] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
125 Schindler V, Runggaldier D, Bianca A, Becker AS, Murray F, Savarino E, Pohl D. Opioid Treatment and Excessive Alcohol Consumption Are Associated With Esophagogastric Junction Disorders. J Neurogastroenterol Motil 2019;25:205-11. [PMID: 30982239 DOI: 10.5056/jnm18150] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
126 Pluta KD, Ciezkowska M, Wisniewska M, Wencel A, Pijanowska DG. Cell-based clinical and experimental methods for assisting the function of impaired livers – Present and future of liver support systems. Biocybernetics and Biomedical Engineering 2021;41:1322-46. [DOI: 10.1016/j.bbe.2021.06.005] [Reference Citation Analysis]
127 Zupo R, Castellana F, De Nucci S, De Pergola G, Lozupone M, Bortone I, Castellana M, Sborgia G, Lampignano L, Giannelli G, Panza F, Sardone R. Liver Fibrosis and 8-Year All-Cause Mortality Trajectories in the Aging Cohort of the Salus in Apulia Study. Biomedicines 2021;9:1617. [PMID: 34829846 DOI: 10.3390/biomedicines9111617] [Reference Citation Analysis]
128 Lazarus JV, Palayew A, Carrieri P, Ekstedt M, Marchesini G, Novak K, Ratziu V, Romero-Gómez M, Tacke F, Zelber-Sagi S, Cortez-Pinto H, Anstee QM. European 'NAFLD Preparedness Index' - Is Europe ready to meet the challenge of fatty liver disease? JHEP Rep 2021;3:100234. [PMID: 33733078 DOI: 10.1016/j.jhepr.2021.100234] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
129 Hagström H, Lindfors A, Holmer M, Bengtsson B, Björkström K, Hegmar H, von Seth E. Etiologies and outcomes of cirrhosis in a large contemporary cohort. Scand J Gastroenterol 2021;56:727-32. [PMID: 33872099 DOI: 10.1080/00365521.2021.1912167] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
130 Patten DA, Wilkinson AL, O'Keeffe A, Shetty S. Scavenger Receptors: Novel Roles in the Pathogenesis of Liver Inflammation and Cancer. Semin Liver Dis 2021. [PMID: 34553345 DOI: 10.1055/s-0041-1733876] [Reference Citation Analysis]
131 García-Román R, Francés R. Acetaminophen-Induced Liver Damage in Hepatic Steatosis. Clin Pharmacol Ther 2020;107:1068-81. [PMID: 31638270 DOI: 10.1002/cpt.1701] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
132 Moon AM, Singal AG, Tapper EB. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin Gastroenterol Hepatol. 2020;18:2650-2666. [PMID: 31401364 DOI: 10.1016/j.cgh.2019.07.060] [Cited by in Crossref: 102] [Cited by in F6Publishing: 110] [Article Influence: 34.0] [Reference Citation Analysis]
133 Popoiag RE, Suceveanu AI, Suceveanu AP, Micu SI, Voinea F, Mazilu L, Petcu LC, Panaitescu E, Cozaru G, Fierbințeanu-Braticevici C. Predictors of spontaneous bacterial peritonitis in Romanian adults with liver cirrhosis: Focus on the neutrophil-to-lymphocyte ratio. Exp Ther Med 2021;22:983. [PMID: 34345265 DOI: 10.3892/etm.2021.10415] [Reference Citation Analysis]
134 Mikami K, Endo T, Sawada N, Igarashi G, Kimura M, Hasegawa T, Iino C, Tomita H, Sawada K, Nakaji S, Matsuzaka M, Torok NJ, Fukuda S. Leptin/adiponectin ratio correlates with hepatic steatosis but not arterial stiffness in nonalcoholic fatty liver disease in Japanese population. Cytokine 2020;126:154927. [PMID: 31756645 DOI: 10.1016/j.cyto.2019.154927] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
135 Ganne-Carrié N, Nahon P. Hepatocellular carcinoma in the setting of alcohol-related liver disease. J Hepatol 2019;70:284-93. [PMID: 30658729 DOI: 10.1016/j.jhep.2018.10.008] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 32.0] [Reference Citation Analysis]
136 Claveria-Cabello A, Colyn L, Uriarte I, Latasa MU, Arechederra M, Herranz JM, Alvarez L, Urman JM, Martinez-Chantar ML, Banales JM, Sangro B, Rombouts K, Oyarzabal J, Marin JJG, Berasain C, Avila MA, Fernandez-Barrena MG. Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis. Cancers (Basel) 2020;12:E3748. [PMID: 33322158 DOI: 10.3390/cancers12123748] [Reference Citation Analysis]
137 Afonso MB, Castro RE, Rodrigues CMP. Processes exacerbating apoptosis in non-alcoholic steatohepatitis. Clin Sci (Lond) 2019;133:2245-64. [PMID: 31742325 DOI: 10.1042/CS20190068] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
138 Aghabi YO, Yasin A, Kennedy JI, Davies SP, Butler AE, Stamataki Z. Targeting Enclysis in Liver Autoimmunity, Transplantation, Viral Infection and Cancer. Front Immunol 2021;12:662134. [PMID: 33953725 DOI: 10.3389/fimmu.2021.662134] [Reference Citation Analysis]
139 Tonon M, Piano S. Alcohol-related cirrhosis: The most challenging etiology of cirrhosis is more burdensome than ever. Clin Mol Hepatol 2021;27:94-6. [PMID: 33317236 DOI: 10.3350/cmh.2020.0305] [Reference Citation Analysis]
140 Durand F, Antoine C, Soubrane O. Liver Transplantation in France. Liver Transpl 2019;25:763-70. [DOI: 10.1002/lt.25419] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
141 Vaz J, Eriksson B, Strömberg U, Buchebner D, Midlöv P. Incidence, aetiology and related comorbidities of cirrhosis: a Swedish population-based cohort study. BMC Gastroenterol 2020;20:84. [PMID: 32245414 DOI: 10.1186/s12876-020-01239-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
142 Odagiri N, Matsubara T, Sato-Matsubara M, Fujii H, Enomoto M, Kawada N. Anti-fibrotic treatments for chronic liver diseases: The present and the future. Clin Mol Hepatol 2021;27:413-24. [PMID: 33317250 DOI: 10.3350/cmh.2020.0187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
143 Ballester-Clau R, Torres Vicente G, Cucala Ramos M, Aracil Blanch C, Miñana Calafat JM, Pijoan Comas E, Reñé Espinet JM, Planella de Rubinat M. Efficacy and Safety of Treatment With Ferric Carboxymaltose in Patients With Cirrhosis and Gastrointestinal Bleeding. Front Med (Lausanne) 2020;7:128. [PMID: 32363194 DOI: 10.3389/fmed.2020.00128] [Reference Citation Analysis]
144 Wang YJ, Zhu YB, Wei WJ. Effect of non-selective β-receptor blockers on inflammatory factors and prognosis in advanced chronic liver disease. Shijie Huaren Xiaohua Zazhi 2021; 29(19): 1110-1117 [DOI: 10.11569/wcjd.v29.i19.1110] [Reference Citation Analysis]
145 Kasper P, Tacke F, Michels G. [Management of acutely decompensated liver cirrhosis in emergency and critical care medicine]. Med Klin Intensivmed Notfmed 2021. [PMID: 34636958 DOI: 10.1007/s00063-021-00876-3] [Reference Citation Analysis]
146 Kirschner M, do Ó Hartmann N, Parmentier S, Hart C, Henze L, Bisping G, Griesshammer M, Langer F, Pabinger-Fasching I, Matzdorff A, Riess H, Koschmieder S. Primary Thromboprophylaxis in Patients with Malignancies: Daily Practice Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO), the Society of Thrombosis and Hemostasis Research (GTH), and the Austrian Society of Hematology and Oncology (ÖGHO). Cancers (Basel) 2021;13:2905. [PMID: 34200741 DOI: 10.3390/cancers13122905] [Reference Citation Analysis]
147 Fan Y, Yan LT, Yao Z, Xiong GY. Biochanin A Regulates Cholesterol Metabolism Further Delays the Progression of Nonalcoholic Fatty Liver Disease. Diabetes Metab Syndr Obes 2021;14:3161-72. [PMID: 34276221 DOI: 10.2147/DMSO.S315471] [Reference Citation Analysis]
148 Lorée H, Bastard C, Miette V, Sandrin L. Vibration-Guided Transient Elastography: A Novel Fibroscan® Examination with Improved Guidance for Liver Stiffness Measurement. Ultrasound Med Biol 2020;46:2193-206. [PMID: 32536508 DOI: 10.1016/j.ultrasmedbio.2020.04.010] [Reference Citation Analysis]
149 Seddek A. Liver fibrosis causes periportalization of lobular zonation. EXCLI J 2019;18:1104-6. [PMID: 31938031 DOI: 10.17179/excli2019-2078] [Reference Citation Analysis]
150 Kasper P, Steffen HM, Michels G. [Cirrhotic cardiomyopathy]. Dtsch Med Wochenschr 2021;146:1070-6. [PMID: 34416775 DOI: 10.1055/a-1321-9523] [Reference Citation Analysis]
151 Coelho I, Duarte N, Macedo MP, Penha-Gonçalves C. Insights into Macrophage/Monocyte-Endothelial Cell Crosstalk in the Liver: A Role for Trem-2. J Clin Med 2021;10:1248. [PMID: 33802948 DOI: 10.3390/jcm10061248] [Reference Citation Analysis]
152 Yanes M, Santoni G, Maret-Ouda J, Ness-Jensen E, Färkkilä M, Lynge E, Pukkala E, Romundstad P, Tryggvadóttir L, -Chelpin MVE, Lagergren J. Survival after antireflux surgery versus medication in patients with reflux oesophagitis or Barrett's oesophagus: multinational cohort study. Br J Surg 2021;108:864-70. [PMID: 33724340 DOI: 10.1093/bjs/znab024] [Reference Citation Analysis]
153 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu., Clinical Practice Guideline Panel., Chair:., EASL Governing Board representative:., Panel members:. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 2021;75:659-89. [PMID: 34166721 DOI: 10.1016/j.jhep.2021.05.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 16.0] [Reference Citation Analysis]
154 Balvey A, Fernandez M. Translational Control in Liver Disease. Front Physiol 2021;12:795298. [PMID: 34912244 DOI: 10.3389/fphys.2021.795298] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
155 Zhu J, Wang P, Ye H, Shi J, Wang X, Wang K, Duan F, Yang Q, Sun G, Zhang J. Trend of the mortality of major liver diseases and its impact on life expectancy in China from 2006 to 2017. J Public Health (Oxf) 2021:fdaa261. [PMID: 33454770 DOI: 10.1093/pubmed/fdaa261] [Reference Citation Analysis]
156 Bernardo S, Crespo R, Saraiva S, Barata R, Gonçalves S, Nogueira P, Cortez-Pinto H, Machado MV. Outcomes of excessive alcohol drinkers without baseline evidence of chronic liver disease after 15 years follow-up: Heavy burden of cancer and liver disease mortality. PLoS One 2021;16:e0252218. [PMID: 34033642 DOI: 10.1371/journal.pone.0252218] [Reference Citation Analysis]
157 Melo L, Bilici M, Hagar A, Klaunig JE. The effect of endurance training on non-alcoholic fatty liver disease in mice. Physiol Rep 2021;9:e14926. [PMID: 34342164 DOI: 10.14814/phy2.14926] [Reference Citation Analysis]
158 Alferink LJM, Kiefte-de Jong JC, Erler NS, de Knegt RJ, Hoorn EJ, Ikram MA, Janssen HLA, Metselaar HJ, Franco OH, Darwish Murad S. Diet-Dependent Acid Load-The Missing Link Between an Animal Protein-Rich Diet and Nonalcoholic Fatty Liver Disease? J Clin Endocrinol Metab 2019;104:6325-37. [PMID: 30977830 DOI: 10.1210/jc.2018-02792] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
159 Goudsmit BFJ, Putter H, Tushuizen ME, de Boer J, Vogelaar S, Alwayn IPJ, van Hoek B, Braat AE. Validation of the Model for End-stage Liver Disease sodium (MELD-Na) score in the Eurotransplant region. Am J Transplant 2021;21:229-40. [PMID: 32529758 DOI: 10.1111/ajt.16142] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
160 Torres S, Abdullah Z, Brol MJ, Hellerbrand C, Fernandez M, Fiorotto R, Klein S, Königshofer P, Liedtke C, Lotersztajn S, Nevzorova YA, Schierwagen R, Reiberger T, Uschner FE, Tacke F, Weiskirchen R, Trebicka J. Recent Advances in Practical Methods for Liver Cell Biology: A Short Overview. Int J Mol Sci 2020;21:E2027. [PMID: 32188134 DOI: 10.3390/ijms21062027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
161 Thiele M, Johansen S, Gudmann NS, Madsen B, Kjaergaard M, Nielsen MJ, Leeming DJ, Jacobsen S, Bendtsen F, Møller S, Detlefsen S, Karsdal M, Krag A; GALAXY Consortium. Progressive alcohol-related liver fibrosis is characterised by imbalanced collagen formation and degradation. Aliment Pharmacol Ther 2021;54:1070-80. [PMID: 34428307 DOI: 10.1111/apt.16567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
162 Ventura-Cots M, Ballester-Ferré MP, Ravi S, Bataller R. Public health policies and alcohol-related liver disease. JHEP Rep 2019;1:403-13. [PMID: 32039391 DOI: 10.1016/j.jhepr.2019.07.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
163 Wu LJ, Chen ZY, Wang Y, Zhao JG, Xie XZ, Chen G. Organoids of liver diseases: From bench to bedside. World J Gastroenterol 2019; 25(16): 1913-1927 [PMID: 31086460 DOI: 10.3748/wjg.v25.i16.1913] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
164 Laroia ST, Vellore Srinivasan S, Yadav K, Rastogi A, Kumar S, Kumar G, Kumar M. Performance of shear wave elastography: A single centre pilot study of mixed etiology liver disease patients with normal BMI. Australas J Ultrasound Med 2021;24:120-36. [PMID: 34765422 DOI: 10.1002/ajum.12244] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Brunsing RL, Chen DH, Schlein A, Wolfson T, Gamst A, Mamidipalli A, Violi NV, Marks RM, Taouli B, Loomba R, Kono Y, Sirlin CB. Gadoxetate-enhanced Abbreviated MRI for Hepatocellular Carcinoma Surveillance: Preliminary Experience. Radiol Imaging Cancer 2019;1:e190010. [PMID: 33778680 DOI: 10.1148/rycan.2019190010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
166 Vecerzan L, Olteanu A, Maniu I, Boicean A, Cipăian CR, Dura H, Fleacă SR, Mihăilă RG. Thrombin Generation in Chronic Liver Diseases-A Pilot Study. Healthcare (Basel) 2021;9:550. [PMID: 34066706 DOI: 10.3390/healthcare9050550] [Reference Citation Analysis]
167 Palma E, Riva A, Moreno C, Odena G, Mudan S, Manyakin N, Miquel R, Degré D, Trepo E, Sancho-Bru P, Altamirano J, Caballeria J, Zamalloa A, Menon K, Heaton N, Williams R, Bataller R, Chokshi S. Perturbations in Mitochondrial Dynamics Are Closely Involved in the Progression of Alcoholic Liver Disease. Alcohol Clin Exp Res 2020;44:856-65. [PMID: 32020641 DOI: 10.1111/acer.14299] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
168 Liu Z, Jiang Y, Yuan H, Fang Q, Cai N, Suo C, Jin L, Zhang T, Chen X. The trends in incidence of primary liver cancer caused by specific etiologies: Results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention. J Hepatol. 2019;70:674-683. [PMID: 30543829 DOI: 10.1016/j.jhep.2018.12.001] [Cited by in Crossref: 123] [Cited by in F6Publishing: 126] [Article Influence: 30.8] [Reference Citation Analysis]
169 Ahmad B, Ilahi I, Yousafzai AM, Attaullah M, Rahim A, Naz D, Hazrat A, Batiha GE, Nassan MA, Khalil AAK. Protective effects of Zizyphus oxyphyla on liver and kidney related serum biomarkers in (CCl4) intoxicate rabbits. Braz J Biol 2021;83:e246980. [PMID: 34468522 DOI: 10.1590/1519-6984.246980] [Reference Citation Analysis]
170 Kupczyk PA, Mesropyan N, Isaak A, Endler C, Faron A, Kuetting D, Sprinkart AM, Mädler B, Thomas D, Attenberger UI, Luetkens JA. Quantitative MRI of the liver: Evaluation of extracellular volume fraction and other quantitative parameters in comparison to MR elastography for the assessment of hepatopathy. Magn Reson Imaging 2021;77:7-13. [PMID: 33309923 DOI: 10.1016/j.mri.2020.12.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
171 Romero-Gomez M, Kachru N, Zamorano MA, Darba J, Shreay S. Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain. Medicine (Baltimore) 2020;99:e23506. [PMID: 33327291 DOI: 10.1097/MD.0000000000023506] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
172 Lazarus JV, Ekstedt M, Marchesini G, Mullen J, Novak K, Pericàs JM, Roel E, Romero-Gómez M, Ratziu V, Tacke F, Cortez-Pinto H, Anstee QM; EASL International Liver Foundation NAFLD Policy Review Collaborators. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. J Hepatol 2020;72:14-24. [PMID: 31518646 DOI: 10.1016/j.jhep.2019.08.027] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 16.7] [Reference Citation Analysis]
173 Jachs M, Hartl L, Schaufler D, Desbalmes C, Simbrunner B, Eigenbauer E, Bauer DJM, Paternostro R, Schwabl P, Scheiner B, Bucsics T, Stättermayer AF, Pinter M, Trauner M, Mandorfer M, Reiberger T. Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes. Gut 2021;70:1758-67. [PMID: 33199442 DOI: 10.1136/gutjnl-2020-322712] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
174 Golabi P, Paik JM, Eberly K, de Avila L, Alqahtani SA, Younossi ZM. Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C. Ann Hepatol 2021;27:100556. [PMID: 34800721 DOI: 10.1016/j.aohep.2021.100556] [Reference Citation Analysis]
175 Martínez-Uña M, López-Mancheño Y, Diéguez C, Fernández-Rojo MA, Novelle MG. Unraveling the Role of Leptin in Liver Function and Its Relationship with Liver Diseases. Int J Mol Sci 2020;21:E9368. [PMID: 33316927 DOI: 10.3390/ijms21249368] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
176 Li M, Chen L, Gao Y, Li M, Wang X, Qiang L, Wang X. Recent advances targeting C-C chemokine receptor type 2 for liver diseases in monocyte/macrophage. Liver Int 2020;40:2928-36. [PMID: 33025657 DOI: 10.1111/liv.14687] [Reference Citation Analysis]
177 Koo S, Sharp L, Hull M, Rushton S, Neilson LJ, McPherson S, Rees CJ; OSCAR study team. Uncovering undiagnosed liver disease: prevalence and opportunity for intervention in a population attending colonoscopy. BMJ Open Gastroenterol 2021;8:e000638. [PMID: 34011624 DOI: 10.1136/bmjgast-2021-000638] [Reference Citation Analysis]
178 Brennan PN, MacMillan M, Manship T, Moroni F, Glover A, Graham C, Semple S, Morris DM, Fraser AR, Pass C, McGowan NWA, Turner ML, Lachlan N, Dillon JF, Campbell JDM, Fallowfield JA, Forbes SJ. Study protocol: a multicentre, open-label, parallel-group, phase 2, randomised controlled trial of autologous macrophage therapy for liver cirrhosis (MATCH). BMJ Open 2021;11:e053190. [PMID: 34750149 DOI: 10.1136/bmjopen-2021-053190] [Reference Citation Analysis]
179 Brancaccio G, Vitale A, Signoriello G, Gaeta GB, Cillo U. Changing indications for liver transplant: slow decline of hepatitis viruses in Italy. Infect Dis (Lond) 2020;52:557-62. [PMID: 32401092 DOI: 10.1080/23744235.2020.1763453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
180 Hayward KL, Johnson AL, Horsfall LU, Moser C, Valery PC, Powell EE. Detecting non-alcoholic fatty liver disease and risk factors in health databases: accuracy and limitations of the ICD-10-AM. BMJ Open Gastroenterol 2021;8:e000572. [PMID: 33568418 DOI: 10.1136/bmjgast-2020-000572] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
181 Gnocchi D, Custodero C, Sabbà C, Mazzocca A. Circadian rhythms: a possible new player in non-alcoholic fatty liver disease pathophysiology. J Mol Med (Berl) 2019;97:741-59. [PMID: 30953079 DOI: 10.1007/s00109-019-01780-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
182 Bertuccio P, Alicandro G, Malvezzi M, Carioli G, Boffetta P, Levi F, La Vecchia C, Negri E. Cancer mortality in Europe in 2015 and an overview of trends since 1990. Annals of Oncology 2019;30:1356-69. [DOI: 10.1093/annonc/mdz179] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
183 Orioli R, Solimini AG, Michelozzi P, Forastiere F, Davoli M, Cesaroni G. A cohort study on long-term exposure to air pollution and incidence of liver cirrhosis. Environ Epidemiol 2020;4:e109. [PMID: 33778350 DOI: 10.1097/EE9.0000000000000109] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
184 Trovato GM. Non-alcoholic fatty liver disease and Atherosclerosis at a crossroad: The overlap of a theory of change and bioinformatics. World J Gastrointest Pathophysiol 2020; 11(3): 57-63 [PMID: 32435522 DOI: 10.4291/wjgp.v11.i3.57] [Reference Citation Analysis]
185 Bellan M, Colletta C, Barbaglia MN, Salmi L, Clerici R, Mallela VR, Castello LM, Saglietti G, Carnevale Schianca GP, Minisini R, Pirisi M. Severity of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus: Relationship between Nongenetic Factors and PNPLA3/HSD17B13 Polymorphisms. Diabetes Metab J 2019;43:700-10. [PMID: 31694082 DOI: 10.4093/dmj.2018.0201] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
186 Yang C, Lu Y, Xia H, Liu H, Pan D, Yang X, Sun G. Excess Body Weight and the Risk of Liver Cancer: Systematic Review and a Meta-Analysis of Cohort Studies. Nutr Cancer 2020;72:1085-97. [PMID: 31544511 DOI: 10.1080/01635581.2019.1664602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
187 Sinn DH, Kang D, Guallar E, Chang Y, Ryu S, Zhao D, Hong YS, Cho J, Gwak GY. Alcohol Intake and Mortality in Patients With Chronic Viral Hepatitis: A Nationwide Cohort Study. Am J Gastroenterol 2021;116:329-35. [PMID: 33038136 DOI: 10.14309/ajg.0000000000000966] [Reference Citation Analysis]
188 Rathi S, Hussaini T, Yoshida EM. Granulocyte colony stimulating factor: A potential therapeutic rescue in severe alcoholic hepatitis and decompensated cirrhosis. Ann Hepatol 2021;20:100211. [PMID: 32533952 DOI: 10.1016/j.aohep.2020.04.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
189 Ciardullo S, Ronchetti C, Muraca E, Oltolini A, Perra S, Bianconi E, Zerbini F, Cannistraci R, Manzoni G, Gastaldelli A, Lattuada G, Perseghin G. Impact of using different biomarkers of liver fibrosis on hepatologic referral of individuals with severe obesity and NAFLD. J Endocrinol Invest 2020;43:1019-26. [PMID: 32008185 DOI: 10.1007/s40618-020-01188-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
190 Leitão J, Carvalhana S, Cochicho J, Silva AP, Velasco F, Medeiros I, Alves AC, Bourbon M, Oliveiros B, Rodrigues V, Sousa R, Sampaio F, Carvalho A, Cortez-Pinto H. Prevalence and risk factors of fatty liver in Portuguese adults.Eur J Clin Invest. 2020;50:e13235. [PMID: 32289180 DOI: 10.1111/eci.13235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
191 Guillot A, Tacke F. Liver Macrophages: Old Dogmas and New Insights. Hepatol Commun 2019;3:730-43. [PMID: 31168508 DOI: 10.1002/hep4.1356] [Cited by in Crossref: 106] [Cited by in F6Publishing: 105] [Article Influence: 35.3] [Reference Citation Analysis]
192 Istrate A, Rădulescu AL. A comparison of hepatitis E and A in a teaching hospital in Northwestern Romania. Acute hepatitis E - a mild disease? Med Pharm Rep 2020;93:30-8. [PMID: 32133444 DOI: 10.15386/mpr-1487] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
193 Paik JM, Golabi P, Younossi Y, Srishord M, Mishra A, Younossi ZM. The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007-2017. Hepatol Commun 2020;4:1769-80. [PMID: 33305148 DOI: 10.1002/hep4.1599] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
194 Morales-Arraez D, Nieto Bujalance Y, Diaz-Flores F, de Vera A, Jiménez A, Garcia Dopico JA, Quintero E, Hernández-Guerra M. Risk of liver fibrosis progression in patients with suboptimal diagnosis of hepatitis C virus infection. Eur J Gastroenterol Hepatol 2020;32:528-34. [PMID: 31490420 DOI: 10.1097/MEG.0000000000001534] [Reference Citation Analysis]
195 Rodríguez M, González-Diéguez ML, Varela M, Cadahía V, Andrés-Vizán SM, Mesa A, Castaño A, Alvarez-Navascués C. Impact of Alcohol Abstinence on the Risk of Hepatocellular Carcinoma in Patients With Alcohol-Related Liver Cirrhosis. Am J Gastroenterol 2021. [PMID: 34569986 DOI: 10.14309/ajg.0000000000001399] [Reference Citation Analysis]
196 Engelmann C, Herber A, Franke A, Bruns T, Schiefke I, Zipprich A, Zeuzem S, Goeser T, Canbay A, Berg C, Trebicka J, Uschner FE, Chang J, Mueller T, Aehling N, Schmelzle M, Splith K, Lammert F, Lange CM, Sarrazin C, Trautwein C, Manns M, Häussinger D, Pfeiffenberger J, Galle PR, Schmiedeknecht A, Berg T. Granulocyte-Colony Stimulating Factor (G-CSF) to treat acute-on-chronic liver failure, a multicenter randomized trial (GRAFT study). J Hepatol 2021:S0168-8278(21)01963-2. [PMID: 34364917 DOI: 10.1016/j.jhep.2021.07.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
197 Younossi ZM. Non-alcoholic fatty liver disease – A global public health perspective. Journal of Hepatology 2019;70:531-44. [DOI: 10.1016/j.jhep.2018.10.033] [Cited by in Crossref: 452] [Cited by in F6Publishing: 433] [Article Influence: 150.7] [Reference Citation Analysis]
198 Li J, Dong S, Ye M, Peng G, Luo J, Wang C, Wang J, Zhao Q, Chang Y, Wang H. MicroRNA-489-3p Represses Hepatic Stellate Cells Activation by Negatively Regulating the JAG1/Notch3 Signaling Pathway. Dig Dis Sci 2021;66:143-50. [PMID: 32144602 DOI: 10.1007/s10620-020-06174-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
199 Hagström H, Andreasson A. Is teenage heavy drinking more hazardous than we thought? Expert Rev Gastroenterol Hepatol 2019;13:603-5. [PMID: 31018717 DOI: 10.1080/17474124.2019.1608819] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
200 Duzagac F, Saorin G, Memeo L, Canzonieri V, Rizzolio F. Microfluidic Organoids-on-a-Chip: Quantum Leap in Cancer Research. Cancers (Basel) 2021;13:737. [PMID: 33578886 DOI: 10.3390/cancers13040737] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
201 Strathearn LS, Stepanov AI, Font-Burgada J. Inflammation in Primary and Metastatic Liver Tumorigenesis-Under the Influence of Alcohol and High-Fat Diets. Nutrients 2020;12:E933. [PMID: 32230953 DOI: 10.3390/nu12040933] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
202 Popoiag RE, Panaitescu E, Suceveanu AI, Suceveanu AP, Micu SI, Mazilu L, Parepa I, Voinea F, Costea DO, Enache F, Fierbințeanu-Braticevici C. Spontaneous bacterial peritonitis mortality trends of cirrhotic patients in the last decade in Constanta County. Exp Ther Med 2021;22:732. [PMID: 34007340 DOI: 10.3892/etm.2021.10164] [Reference Citation Analysis]
203 Iacob S, Beckebaum S, Iacob R, Gheorghe C, Cicinnati V, Popescu I, Gheorghe L. Genetic and Life Style Risk Factors for Recurrent Non-alcoholic Fatty Liver Disease Following Liver Transplantation. Front Nutr 2022;8:787430. [DOI: 10.3389/fnut.2021.787430] [Reference Citation Analysis]
204 Hagymási K. The Nobel Prize in Physiology or Medicine-2020. Struct Chem 2021;:1-5. [PMID: 33584076 DOI: 10.1007/s11224-021-01731-z] [Reference Citation Analysis]
205 Zelber-Sagi S. Dietary Treatment for NAFLD: New Clinical and Epidemiological Evidence and Updated Recommendations. Semin Liver Dis 2021;41:248-62. [PMID: 34139786 DOI: 10.1055/s-0041-1729971] [Reference Citation Analysis]
206 Pawlotsky J, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology 2020;73:1170-218. [DOI: 10.1016/j.jhep.2020.08.018] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 56.5] [Reference Citation Analysis]
207 Yan Y, Ren L, Liu Y, Liu L. Long non-coding RNA CRNDE as potential biomarkers facilitate inflammation and apoptosis in alcoholic liver disease. Aging (Albany NY) 2021;13:23233-44. [PMID: 34633988 DOI: 10.18632/aging.203614] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
208 Teschke R. Alcoholic Liver Disease: Current Mechanistic Aspects with Focus on Their Clinical Relevance. Biomedicines 2019;7:E68. [PMID: 31491888 DOI: 10.3390/biomedicines7030068] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
209 Popa A, Șirli R, Popescu A, Bâldea V, Lupușoru R, Bende F, Cotrău R, Sporea I. Ultrasound-Based Quantification of Fibrosis and Steatosis with a New Software Considering Transient Elastography as Reference in Patients with Chronic Liver Diseases. Ultrasound Med Biol 2021;47:1692-703. [PMID: 33832824 DOI: 10.1016/j.ultrasmedbio.2021.02.029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
210 Katarey D, Jalan R. Non-selective beta blockers in cirrhosis: time to extend the indications? Ann Transl Med 2019;7:S355. [PMID: 32016073 DOI: 10.21037/atm.2019.09.56] [Reference Citation Analysis]
211 Borrell C, Palència L, Bosakova L, Gotsens M, Morrison J, Costa C, Dzurova D, Deboosere P, Lustigova M, Marí-Dell'Olmo M, Rodopoulou S, Santana P. Socioeconomic Inequalities in Chronic Liver Diseases and Cirrhosis Mortality in European Urban Areas before and after the Onset of the 2008 Economic Recession. Int J Environ Res Public Health 2021;18:8801. [PMID: 34444557 DOI: 10.3390/ijerph18168801] [Reference Citation Analysis]
212 Zivko C, Fuhrmann G, Luciani P. Liver-derived extracellular vesicles: A cell by cell overview to isolation and characterization practices. Biochimica et Biophysica Acta (BBA) - General Subjects 2021;1865:129559. [DOI: 10.1016/j.bbagen.2020.129559] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
213 De Vincentis A, Costanzo L, Vespasiani-Gentilucci U, Picardi A, Bandinelli S, Ferrucci L, Antonelli Incalzi R, Pedone C. Association between non-invasive liver fibrosis scores and occurrence of health adverse outcomes in older people. Dig Liver Dis 2019;51:1330-6. [PMID: 30808572 DOI: 10.1016/j.dld.2019.01.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
214 Mårdh O, Quinten C, Amato-Gauci AJ, Duffell E. Mortality from liver diseases attributable to hepatitis B and C in the EU/EEA - descriptive analysis and estimation of 2015 baseline. Infect Dis (Lond) 2020;52:625-37. [PMID: 32644030 DOI: 10.1080/23744235.2020.1766104] [Reference Citation Analysis]
215 Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70:151-171. [PMID: 30266282 DOI: 10.1016/j.jhep.2018.09.014] [Cited by in Crossref: 615] [Cited by in F6Publishing: 559] [Article Influence: 153.8] [Reference Citation Analysis]